HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus

フルテキスト
63_EJ16-0266.pdf823.14 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/68407

タイトル: Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus
著者: Koyanagawa, Naohide 著作を一覧する
Miyoshi, Hideaki 著作を一覧する
Ono, Kota 著作を一覧する
Nakamura, Akinobu 著作を一覧する
Cho, Kyu Yong 著作を一覧する
Yamamoto, Kohei 著作を一覧する
Takano, Yoshinari 著作を一覧する
Dan-Noura, Midori 著作を一覧する
Atsumi, Tatsuya 著作を一覧する
キーワード: Vildagliptin
Sitagliptin
Mean amplitude of glycemic excursions (MAGE)
発行日: 2016年 8月
出版者: The Japan Endocrine Society
誌名: Endocrine Journal
巻: 63
号: 8
開始ページ: 747
終了ページ: 753
出版社 DOI: 10.1507/endocrj.EJ16-0266
抄録: The dipeptidyl peptidase-4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus. Patients receiving standard doses of sitagliptin plus insulin may require increased doses of sitagliptin or switching to vildagliptin to improve blood glucose control. This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin. This prospective, randomized, parallel-group comparison trial enrolled 33 type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin. Seventeen patients were randomized to 50 mg vildagliptin twice daily, and 16 to 100 mg sitagliptin once daily, and evaluated by continuous glucose monitoring at baseline and after 8 weeks. The primary end-point was the change in mean amplitude of glycemic excursions (MAGE). MAGE decreased from baseline in both the vildagliptin (-13.4 ± 35.7 mg/dL) and sitagliptin (-8.4 ± 24.3 mg/dL) groups, but neither within- nor between-group changes were statistically significant. Similarly, the areas under the curve for blood glucose levels ≥180 mg/dL and <70 mg/dL tended to improve in both groups, but these differences were not statistically significant. In contrast, HbA1c was significantly reduced only in the vildagliptin group, from 7.1 ± 0.6% at baseline to 6.8 ± 0.6% at 8 weeks (p=0.006). Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin.
資料タイプ: article
URI: http://hdl.handle.net/2115/68407
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学